Venus Remedies finds cancer cure technology

Chandigarh based Venus Remedies Limited, counted among the top 50 Indian Pharma companies having manufacturing facilities here and in Germany with a turnover of Rs 357 crores in 2011 has come up with a platform patent protected technology called Drug-Protein-Polymer-Conjugate (DPPC).which will help in alleviating cancer and receptor diseases by a specific and selective targeting.
Pawan Chaudhary, CMD, Venus Remedies said that "the demonstrable efficacy in pre-clinical proof of concept studies and an imminent entry into clinical phase of the first DPPC based therapy is commendable achievement of team VMRC. The company is keen to bring this wonder therapy to the market for the benefit of the mankind and would be seeking appropriate collaborations for co-development or technology commercialization of the therapy".
Dr. Manu Chaudhary, Joint Managing Director and Direct Rsearch said that "this platform technology holds its essence, with its significant potential to conjugate a wide range of drugs, thereby, not only reducing the amount of the drug to be targeted but will also be very cost-effective." She said that Venus has come up a platform technology that would bring revolution to the existing target based therapies, with its pronounced therapeutic efficacy, reduced side effects due to a reduction in dose by 4-6 times. It would be a life saving drug within reach of the common man.
Dr.Mufti Suhail Sayeed, Vice-President, Venus Remedies Limited disclosed that "this is a novel concept of triple conjugate-Drug-Protein-Polymer-Conjugate (DPPC). Triple conjugate employs a protein moiety capable of binding selectively to a particular target site, a polymer moiety covalently linked to a protein, and an active drug moiety. "